CareCloud Inc (CCLD)

NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-10-23

$1.770.00%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge CareCloud Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	33.83M
EPS	—	0.125
FY 2026 · Annual
Revenue	$128M–$132M	130.45M
EPS	$0.2–$0.23GAAP	0.275
EBITDA	$29M–$31Mnon-GAAP	—
FY 2027 · Annual
Revenue	—	142.86M
EPS	—	0.305

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Adjusted EBITDA of $29M to $31M in 2026	Adjusted EBITDA is targeted at $29 to $31 million.	Intact	Adjusted EBITDA falls below $27M in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Adjusted EBITDA was $11.3 million in first half 2026, slightly below $12.1 million in first half 2025. Management reaffirmed full-year 2026 adjusted EBITDA guidance of $29–$31 million. The trajectory shows mixed progress with some pressure in early 2026 but management expects improvement. Delivery assessment Oct 24, 2026
Increase EPS to $0.20–$0.23 in 2026	A primary condition in CareCloud Inc's published investment case. The stated target is EPS between $0.20 and $0.23.	Intact	EPS falls below $0.10 in FY26	Diluted EPS: $0.00 per share FY2026-Q2; GAAP. Published target: EPS between $0.20 and $0.23. Target period is not explicitly aligned with this observation. Source published Aug 6, 20260 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 1d7b6756-43d5-4408-8c92-d0f0ba039e17. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Management reaffirmed 2026 EPS guidance of $0.20–$0.23, a 100-130% increase from $0.10 in 2025. Actual GAAP EPS was $0.00 in 2026-Q2 and ($0.01) in 2026-Q1, reflecting early-year investment impacts but consistent with management's expectation of growth. The trajectory is delivering with reaffirmed guidance and improving profitability. Delivery assessment Oct 24, 2026
Successful integration of Empower Healthcare acquisition	The company recently acquired Empower Healthcare to support growth.	Intact	Acquisition fails to contribute or causes material losses in FY26	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Achieve revenue of $128M to $132M in 2026	A primary condition in CareCloud Inc's published investment case. The stated target is Revenue between $128M and $132M.	Intact	Revenue falls below $120M in FY26	Revenue: $31.88M FY2026-Q2; GAAP. Published target: Revenue between $128M and $132M. Target period is not explicitly aligned with this observation. Source published Aug 6, 202631,880,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 1d7b6756-43d5-4408-8c92-d0f0ba039e17. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Revenue grew from $55.0 million in first half 2025 to $63.2 million in first half 2026, a 15% increase. Management reaffirmed full-year 2026 revenue guidance of $128–$132 million. The trajectory shows delivering growth consistent with guidance. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	3 / 3
2026-07-25	Unavailable	Unavailable	3 / 3
2026-07-26	Unavailable	Unavailable	3 / 3
2026-07-27	Unavailable	Unavailable	3 / 3
2026-07-28	Unavailable	Unavailable	3 / 3
2026-07-29	Unavailable	Unavailable	3 / 3
2026-07-30	Unavailable	Unavailable	3 / 3
2026-07-31	Unavailable	Unavailable	3 / 3
2026-08-01	Unavailable	Unavailable	3 / 3
2026-08-02	Unavailable	Unavailable	3 / 3
2026-08-03	Unavailable	Unavailable	3 / 3
2026-08-04	Unavailable	Unavailable	3 / 3
2026-08-05	Unavailable	Unavailable	3 / 3
2026-08-06	Unavailable	Unavailable	3 / 3
2026-08-07	Unavailable	Unavailable	3 / 3
2026-08-08	Unavailable	Unavailable	3 / 3
2026-08-09	Unavailable	Unavailable	3 / 3
2026-08-10	Unavailable	Unavailable	3 / 3
2026-08-11	Unavailable	Unavailable	3 / 3
2026-08-12	Unavailable	Unavailable	3 / 3
2026-08-13	Unavailable	Unavailable	3 / 3
2026-08-14	Unavailable	Unavailable	3 / 3
2026-08-15	Unavailable	Unavailable	3 / 3
2026-08-16	Unavailable	Unavailable	3 / 3
2026-08-17	Unavailable	Unavailable	3 / 3
2026-08-18	Unavailable	Unavailable	3 / 3
2026-08-19	Unavailable	Unavailable	3 / 3
2026-08-20	Unavailable	Unavailable	3 / 3
2026-08-21	Unavailable	Unavailable	3 / 3
2026-08-22	Unavailable	Unavailable	3 / 3
2026-08-23	Unavailable	Unavailable	3 / 3
2026-08-24	Unavailable	Unavailable	3 / 3
2026-08-25	Unavailable	Unavailable	3 / 3
2026-08-26	Unavailable	Unavailable	3 / 3
2026-08-27	Unavailable	Unavailable	3 / 3
2026-08-28	Unavailable	Unavailable	3 / 3
2026-08-29	Unavailable	Unavailable	3 / 3
2026-08-30	Unavailable	Unavailable	3 / 3
2026-08-31	Unavailable	Unavailable	3 / 3
2026-09-01	Unavailable	Unavailable	3 / 3
2026-09-02	Unavailable	Unavailable	3 / 3
2026-09-03	Unavailable	Unavailable	3 / 3
2026-09-04	Unavailable	Unavailable	3 / 3
2026-09-05	Unavailable	Unavailable	3 / 3
2026-09-06	Unavailable	Unavailable	3 / 3
2026-09-07	Unavailable	Unavailable	3 / 3
2026-09-08	Unavailable	Unavailable	3 / 3
2026-09-09	Unavailable	Unavailable	3 / 3
2026-09-10	Unavailable	Unavailable	3 / 3
2026-09-11	Unavailable	Unavailable	3 / 3
2026-09-12	Unavailable	Unavailable	3 / 3
2026-09-13	Unavailable	Unavailable	3 / 3
2026-09-14	Unavailable	Unavailable	3 / 3
2026-09-15	Unavailable	Unavailable	3 / 3
2026-09-16	Unavailable	Unavailable	3 / 3
2026-09-17	Unavailable	Unavailable	2 / 2
2026-09-18	Unavailable	Unavailable	2 / 2
2026-09-19	Unavailable	Unavailable	2 / 2
2026-09-20	Unavailable	Unavailable	2 / 2
2026-09-21	Unavailable	Unavailable	2 / 2
2026-09-22	Unavailable	Unavailable	2 / 2
2026-09-23	Unavailable	Unavailable	2 / 2
2026-09-24	Unavailable	Unavailable	2 / 2
2026-09-25	Unavailable	Unavailable	2 / 2
2026-09-26	Unavailable	Unavailable	2 / 2
2026-09-27	Unavailable	Unavailable	2 / 2
2026-09-28	Unavailable	Unavailable	2 / 2
2026-09-29	Unavailable	Unavailable	2 / 2
2026-09-30	Unavailable	Unavailable	2 / 2
2026-10-01	Unavailable	Unavailable	2 / 2
2026-10-02	Unavailable	Unavailable	2 / 2
2026-10-03	Unavailable	Unavailable	2 / 2
2026-10-04	Unavailable	Unavailable	2 / 2
2026-10-05	Unavailable	Unavailable	2 / 2
2026-10-06	Unavailable	Unavailable	2 / 2
2026-10-07	Unavailable	Unavailable	2 / 2
2026-10-08	Unavailable	Unavailable	2 / 2
2026-10-09	Unavailable	Unavailable	2 / 2
2026-10-10	Unavailable	Unavailable	2 / 2
2026-10-11	Unavailable	Unavailable	2 / 2
2026-10-12	Unavailable	Unavailable	2 / 2
2026-10-13	Unavailable	Unavailable	2 / 2
2026-10-14	Unavailable	Unavailable	2 / 2
2026-10-15	Unavailable	Unavailable	2 / 2
2026-10-16	Unavailable	Unavailable	2 / 2
2026-10-17	Unavailable	Unavailable	2 / 2
2026-10-18	Unavailable	Unavailable	2 / 2
2026-10-19	Unavailable	Unavailable	2 / 2
2026-10-20	Unavailable	Unavailable	2 / 2
2026-10-21	Unavailable	Unavailable	2 / 2
2026-10-22	Unavailable	Unavailable	2 / 2
2026-10-23	Unavailable	Unavailable	2 / 2
2026-10-24	Unavailable	Unavailable	2 / 2

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	2	1
2026-06-01	2	1
2026-07-01	2	1
2026-08-01	2	1
2026-09-01	2	1
2026-10-01	2	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Adjusted EBITDA of $29M to $31M in 2026Direct metric needs a verified mapping
Increase EPS to $0.20–$0.23 in 2026Diluted EPS: $0.00 per share
Successful integration of Empower Healthcare acquisitionQualitative condition
Achieve revenue of $128M to $132M in 2026Revenue: $31.88M

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.9%Typical daily move · historical

Downside history

-53.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

CareCloud Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

CCLD is a higher-risk growth business with a cyclical exposure, rather than a steady compounder. The long-term thesis is intact, though recent earnings misses and volatile management execution leave the next steps less certain.

What's priced into CareCloud Inc

The valuation evidence is mixed: CCLD is described as cheap versus peers, while a separate measure shows a 28% premium to peers. Expectations appear below the model’s baseline, and no valuation fragility signals are flagged. The evidence is not strong enough to make a firm valuation call.

What the fundamentals likely do

Near term, revenue growth and reaffirmed 2026 guidance support the operating case, while first-half adjusted EBITDA was below the prior-year level and GAAP earnings were slightly negative. Management expects full-year improvement, but consecutive earnings misses, a CEO transition, and a higher miss risk make execution an important watch point. Over the multi-year view, the thesis depends on sustaining growth and turning that into better profitability.

What CareCloud Inc hinges on

A guidance cut at the next call would weaken confidence, while continued delivery against reaffirmed revenue and earnings goals would support the thesis. A weakening jobs backdrop could weigh on cyclical healthcare names, while continued strong results from sector peers could support sector momentum. Adjusted EBITDA progress and execution through the CEO transition are also key swing factors.